Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) Income from Continuing Operations (2024 - 2025)

Xilio Therapeutics' Income from Continuing Operations history spans 2 years, with the latest figure at 1929000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 86.93% year-over-year to 1929000.0; the TTM value through Sep 2025 reached 43775000.0, changed N/A, while the annual FY2024 figure was 60582000.0, 23.44% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 1929000.0 at Xilio Therapeutics, up from 14366000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1929000.0 in Q3 2025 and bottomed at 17487000.0 in Q1 2024.